Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Prothena Corp (NQ: PRTA ) 20.77 -0.10 (-0.48%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Prothena Corp < Previous 1 2 3 4 5 6 7 Next > Prothena Reports First Quarter 2023 Financial Results and Business Highlights May 04, 2023 From Prothena Corporation plc Via Business Wire 10 Health Care Stocks Whale Activity In Today's Session May 04, 2023 Via Benzinga Prothena Corp Earnings Preview May 03, 2023 Via Benzinga Another Sucess In Alzheimer’s Disease May 03, 2023 Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments? Via Talk Markets Prothena to Report First Quarter 2023 Financial Results on May 4 April 27, 2023 From Prothena Corporation plc Via Business Wire Where Prothena Corp Stands With Analysts April 24, 2023 Via Benzinga The Latest Analyst Ratings for Prothena Corp April 03, 2023 Via Benzinga Earnings Outlook For Prothena Corp February 22, 2023 Via Benzinga Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate February 01, 2023 Via Benzinga Prothena to Participate in 2023 Bank of America Healthcare Conference April 24, 2023 From Prothena Corporation plc Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 April 24, 2023 Via Benzinga Analyst Expectations for Prothena Corp's Future December 21, 2022 Via Benzinga Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know December 21, 2022 Via Benzinga Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial April 13, 2023 From Walgreens Via Business Wire Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023 March 31, 2023 From Prothena Corporation plc Via Business Wire Prothena to Participate in Stifel 2023 Virtual CNS Days March 21, 2023 From Prothena Corporation plc Via Business Wire Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode March 15, 2023 FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for... Via FinancialNewsMedia Exposures COVID-19 Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting March 14, 2023 From Prothena Corporation plc Via Business Wire Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2023 From Prothena Corporation plc Via Business Wire Earnings Scheduled For February 23, 2023 February 23, 2023 Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. Via Benzinga Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 February 16, 2023 From Prothena Corporation plc Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session February 14, 2023 Via Benzinga Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 03, 2023 From Prothena Corporation plc Via Business Wire Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease January 31, 2023 From Prothena Corporation plc Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 January 27, 2023 Via Benzinga Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish January 11, 2023 2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. Via Talk Markets How To Weather These Choppy Markets December 22, 2022 Until we get an absolute bottom in the markets, the best way to avoid experiencing a devastating permanent loss of capital is to keep away from stocks with deteriorating fundamentals and heavy insider... Via Talk Markets Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease December 21, 2022 The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... Via Talk Markets Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares December 14, 2022 From Prothena Corporation plc Via Business Wire Why Prothena Shares Are Trading Lower December 14, 2022 Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by 6.53% to $59.10 during Wednesday morning. The company announced that it has commenced an underwritten public offering of 3,000,000 of... Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.